MG0003 A Phase 3 Randomized Double-Blind Placebo-Controlled Study

Recruiting

18 years - 99 years

All

Phase 3

4 participants needed

1 Location

Brief description of study

This is a Phase 3 study of rozanolixizumab in anti-AChR or anti-MuSK autoantibody-positive patients with generalized MG who experience moderate to severe symptoms and are being considered for treatment with IVIg or PEX. The primary objective of the study is to demonstrate the clinical efficacy of rozanolixizumab in patients with generalized Myasthenia Gravis.

All participants will be consented and enrolled by the Penn PI or Sub-I. Referrals will be accepted but we plan to recruit patients from within Penn Medicine clinics.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: myasthenia gravis
Age: 18 years - 99 years
Gender: All

Updated on 04 Aug 2024. Study ID: 833604

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

MG0003 A Phase 3 Randomized Double-Blind Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis

Brief description of study

Eligibility of study

Find a site

Interested in the study